Nachrichten zur Episurf Medical AB Aktie

Episurf Medical reported Q1 earnings (loss) broadly in line with our expectation, despite somewhat lower sales. While it seems to…

The shareholders of Episurf Medical AB (publ), reg. no. 556767-0541 (“Episurf” or the “Company”), are hereby summoned to the Extraordinary…

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES…

Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Tuesday, 9 April 2024…

Episurf Medical’s annual report for 2023 is available as of today at the company’s website, www.episurf.com.  Episurf Medical has of environmental and…

Episurf Medical (Nasdaq: EPIS B) will attend Life Sciencedagen which is held on March 6, 2024. The company will be…

This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between…

Episurf Medical’s Nomination Committee proposes six regular board members without deputies, including the re-election of Ulf Grunander as chairman of…

Q4 sales were in line with our forecast, but operating expenses were higher. Overall, we believe sales growth will be…

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Survivorship and clinical outcome of a novel personalized metal implant…

Episurf Medical (Nasdaq: EPIS B) will attend Redeye Life Science Day which is held on November 23rd, 2023. The event…

In accordance with the decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The…

Episurf Medical (Nasdaq: EPIS B) will present at Pareto Securities Healthcare Conference on September 14, 2023. The event is arranged…

Episurf Medical (Nasdaq: EPIS B) today announces that the companys first commercial case in the US has been scheduled for…

Episurf Medical (Nasdaq: EPIS B) today announces that the company is implementing a strategic focus that brings an increased focus…

Episurf Medical AB (NASDAQ: EPIS B): During June, shareholders exercised 153,527 warrants (TO4B). The number of shares has increased by…

Press release 30 June 2023 14:50 CEST Correction of previously communicated press release Episurf Medical AB (publ) ("Episurf") announces correction in relation to…

Episurf Medical (NASDAQ: EPIS B) today announces that the Ministry of Health & Prevention in the United Arab Emirates has…

Episurf Medical (Nasdaq: EPIS B) will present at Redeye Growth Day today, June 1st, 2023. The event is arranged by…

Episurf Medical AB (publ) (“Episurf” or the “Company”) held its Annual General Meeting (the “Meeting”) on Thursday, 4 May 2023…

Episurf Medical (Nasdaq: EPIS B) today provides an update on the establishment of a US commercial organisation. In line with…

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the Canadian Intellectual Property Office (CIPO). The patent,…

This English translation of the notice is an unofficial translation of the Swedish original. In case of any discrepancies between…

Episurf Medical (Nasdaq: EPIS B) will present at Innovative Orthopedics on March 21st, 2023. The event is arranged by Redeye…

Episurf Medical (Nasdaq: EPIS B) today announces that the first surgery in Malaysia with the knee implant Episealer® has been…

Episurf Medical (Nasdaq: EPIS B) will attend Stockholm Corporate Finance Life Science Capital Markets Day on March 8th, 2023. The…

The Indian patent office Intellectual Property India has reported that Episurf Medical (NASDAQ: EPIS B) has received another granted patent…

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO).…

Episurf Medical (Nasdaq: EPIS B) today announces that results from a cost utility study, focusing on the health economic aspects…

Episurf Medical (Nasdaq: EPIS B) today announces that the Chairman of the Board of Directors, Dennis Stripe, has informed the…

Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO).…

Episurf Medical AB (NASDAQ: EPIS B): During December, shareholders exercised 256,877 warrants (TO4B). The number of shares has increased by…

Episurf Medical (NASDAQ: EPIS B) today announces that the company has received 510(k) clearance from the US Food and Drug…

Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology will be presented at the ESSKA Speciality Days…

Episurf Medical (Nasdaq: EPIS B) today announces that the Indian authorities have, through their Directorate General of Health Services, Central…

Episurf Medical (Nasdaq: EPIS B) today announces that as it continues development of its MTP implant, the company has added…

Episurf Medical (Nasdaq: EPIS B) will attend Redeye Life Science Day which is held on November 24th, 2022. The event…

Episurf Medical hosted a CMD on 16 November at which it discussed the state of the company and its long-term…

Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® Knee technology and clinical results will be presented at the…

EPISURF MEDICAL AB invites investors, analysts and media to a Capital Markets Day in Stockholm on Wednesday, November 16, 2022…